CA3176586A1 - Procedes de traitement d'infections polymicrobiennes - Google Patents
Procedes de traitement d'infections polymicrobiennesInfo
- Publication number
- CA3176586A1 CA3176586A1 CA3176586A CA3176586A CA3176586A1 CA 3176586 A1 CA3176586 A1 CA 3176586A1 CA 3176586 A CA3176586 A CA 3176586A CA 3176586 A CA3176586 A CA 3176586A CA 3176586 A1 CA3176586 A1 CA 3176586A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- treating
- infections
- polymicrobial infections
- microbes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003322 Coinfection Diseases 0.000 title abstract 4
- 241000894006 Bacteria Species 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
L'invention concerne des procédés de détection et de traitement d'infections polymicrobiennes, une population mixte de microbes (par exemple, des bactéries) étant présente dans un échantillon de patient et les microbes n'étant pas tout d'abord isolés de l'échantillon. Par exemple, la présente invention concerne des infections polymicrobiennes spécifiques et des procédés de traitement desdites infections, un antibiotique particulier ou un groupe d'antibiotiques étant choisi sur la base de la composition des infections polymicrobiennes.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/848,651 | 2020-04-14 | ||
US16/848,651 US11053532B2 (en) | 2017-04-19 | 2020-04-14 | Methods for treating polymicrobial infections |
US202063047846P | 2020-07-02 | 2020-07-02 | |
US63/047,846 | 2020-07-02 | ||
US202063063093P | 2020-08-07 | 2020-08-07 | |
US63/063,093 | 2020-08-07 | ||
US202063111287P | 2020-11-09 | 2020-11-09 | |
US63/111,287 | 2020-11-09 | ||
US202063119328P | 2020-11-30 | 2020-11-30 | |
US63/119,328 | 2020-11-30 | ||
US17/178,091 | 2021-02-17 | ||
US17/178,091 US20210172000A1 (en) | 2017-04-19 | 2021-02-17 | Methods and systems for preparing therapeutic solutions for polymicrobial infections |
PCT/US2021/027336 WO2021211746A1 (fr) | 2020-04-14 | 2021-04-14 | Procédés de traitement d'infections polymicrobiennes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3176586A1 true CA3176586A1 (fr) | 2021-10-21 |
Family
ID=78085362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3176586A Pending CA3176586A1 (fr) | 2020-04-14 | 2021-04-14 | Procedes de traitement d'infections polymicrobiennes |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3176586A1 (fr) |
WO (1) | WO2021211746A1 (fr) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
FR2881755B1 (fr) * | 2005-02-10 | 2012-11-30 | Biomerieux Sa | Milieux pour la detection specifique de micro-organismes resistants |
AT503862B1 (de) * | 2006-07-05 | 2010-11-15 | Arc Austrian Res Centers Gmbh | Pathogen-identifizierung anhand eines 16s oder 18s-rrna mikroarray |
WO2014138119A2 (fr) * | 2013-03-04 | 2014-09-12 | Fry Laboratories, LLC | Procédé et trousse pour la caractérisation de micro-organismes |
US20180135108A1 (en) * | 2014-01-20 | 2018-05-17 | Board Of Trustees Of Michigan State University | Method for detecting bacterial and fungal pathogens |
EP3141612A1 (fr) * | 2015-09-10 | 2017-03-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Procédé et dispositif pour approches de diagnostic à base d'acide nucléique comprenant la détermination d'une condition déviante, notamment d'un état de santé et/ou d'un état pathogène d'un échantillon |
WO2018195343A1 (fr) * | 2017-04-19 | 2018-10-25 | CAP Diagnostics, LLC, dba Pathnostics | Dosage pour l'identification complète de la sensibilité aux antibiotiques |
US11053532B2 (en) * | 2017-04-19 | 2021-07-06 | CAP Diagnostics, LLC | Methods for treating polymicrobial infections |
-
2021
- 2021-04-14 WO PCT/US2021/027336 patent/WO2021211746A1/fr active Application Filing
- 2021-04-14 CA CA3176586A patent/CA3176586A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021211746A1 (fr) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kleinschmidt et al. | Staphylococcus epidermidis as a cause of bacteremia | |
Jørgensen et al. | Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa | |
Stuart et al. | Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin | |
Lépesová et al. | Prevalence of antibiotic-resistant coliform bacteria, Enterococcus spp. and Staphylococcus spp. in wastewater sewerage biofilm | |
Boyle et al. | Low-virulence organisms and periprosthetic joint infection—biofilm considerations of these organisms | |
Sobke et al. | Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline | |
Liu et al. | Tetrasodium EDTA is effective at eradicating biofilms formed by clinically relevant microorganisms from patients’ central venous catheters | |
Garg et al. | Biofilm formation capability of enterococcal strains causing urinary tract infection vis-a-vis colonisation and correlation with enterococcal surface protein gene | |
Månsson et al. | Sequence types of Staphylococcus epidermidis associated with prosthetic joint infections are not present in the laminar airflow during prosthetic joint surgery | |
Zmantar et al. | Multiplex PCR detection of the antibiotic resistance genes in Staphylococcus aureus strains isolated from auricular infections | |
Kitti et al. | Biofilm formation of methicillin-resistant coagulase-negative Staphylococci isolated from clinical samples in Northern Thailand | |
Bartoloni et al. | In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococi, enterococci and Clostridium difficile | |
Yaghoobi et al. | Antibiofilm activity of Dracocephalum polychaetum extract on methicillin-resistant Staphylococcus aureus | |
Farhadian et al. | Determination of vancomycin and methicillin resistance in clinical isolates of Staphylococcus aureus in Iranian hospitals. | |
Yamamichi et al. | Relationship between urinary tract infection categorization and pathogens’ antimicrobial susceptibilities | |
Njoungang et al. | Prevalence and antibiotic resistance patterns of strains of Staphylococcus aureus isolated at the Yaounde Military Hospital, Cameroon | |
CA3176586A1 (fr) | Procedes de traitement d'infections polymicrobiennes | |
Shigemura et al. | Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections | |
Goyal et al. | Detection of clindamycin susceptibility in macrolide resistant phenotypes of Staphylococcus aureus | |
Torabi et al. | Characteristics of methicillin resistant Staphylococcus aureus strains isolated from hospital wastewater in Tehran, Iran | |
WO2022251309A3 (fr) | Compositions pharmaceutiques et leurs utilisations | |
Almuzara et al. | Arcanobacterium hemolyticum: identification and susceptibility to nine antimicrobial agents | |
Ogbolu et al. | Emergence of vancomycin intermediate Staphylococcus aureus (VISA) in clinical isolates of methicillin resistant S. aureus from South Western Region of Nigeria | |
Perez-Hernandez et al. | Low prevalence of vancomycin-resistant enterococci in clinical samples from hospitalized patients of the Canary Islands, Spain | |
Al-Amara | Comparison between phenotype and molecular resistance characteristic in Staphylococcus epidermidis isolates from wound infections in Al-Basrah province, Iraq |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220922 |
|
EEER | Examination request |
Effective date: 20220922 |
|
EEER | Examination request |
Effective date: 20220922 |
|
EEER | Examination request |
Effective date: 20220922 |
|
EEER | Examination request |
Effective date: 20220922 |